CR20200240A - Stable pharmaceutical formulation of a fusion protein - Google Patents

Stable pharmaceutical formulation of a fusion protein

Info

Publication number
CR20200240A
CR20200240A CR20200240A CR20200240A CR20200240A CR 20200240 A CR20200240 A CR 20200240A CR 20200240 A CR20200240 A CR 20200240A CR 20200240 A CR20200240 A CR 20200240A CR 20200240 A CR20200240 A CR 20200240A
Authority
CR
Costa Rica
Prior art keywords
fusion protein
formulation
etanercept
pharmaceutical formulation
stable pharmaceutical
Prior art date
Application number
CR20200240A
Other languages
Spanish (es)
Inventor
Hernández Mariana Patricia Miranda
García Víctor Raúl Campos
Blanca Sánchez Lilia Tierra
Lara Nelly Piña
Flores Rodolfo Daniel Salazar
Ortíz Luis Francisco Flores
Ramírez Néstor Octavio Pérez
De La Garza Carlos Eduardo Espinoza
Alcántara María De Lourdes Muciño
Ceballos Rodolfo Alazar
Original Assignee
Probiomed S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiomed S A De C V filed Critical Probiomed S A De C V
Publication of CR20200240A publication Critical patent/CR20200240A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Abstract

The present invention describes a new liquid formulation of etanercept, a recombinant fusion protein TNFR:Fc targeted against TNFa in a high concentration (20 to 100 mg/mL), in the presence of a pH buffer solution of histidine or succinate, which maintain a pH between 5.8 and 6.8, with added polysorbate, sucrose or trehalose, and mannitol used as a tonicity agent. This formulation uses fewer excipients than the formulations described in the prior art and in a combination that has never been used before. In addition, the formulation has a reduced percentage of impurities and greater thermostability than the liquid formula of Enbrel®, while maintaining the physicochemical identity and biological potency of etanercept.
CR20200240A 2017-10-31 2018-10-31 Stable pharmaceutical formulation of a fusion protein CR20200240A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2017013995A MX2017013995A (en) 2017-10-31 2017-10-31 Stable pharmaceutical formulation of a fusion protein.
PCT/IB2018/058555 WO2019087108A1 (en) 2017-10-31 2018-10-31 Stable pharmaceutical formulation of a fusion protein

Publications (1)

Publication Number Publication Date
CR20200240A true CR20200240A (en) 2020-09-15

Family

ID=66331521

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200240A CR20200240A (en) 2017-10-31 2018-10-31 Stable pharmaceutical formulation of a fusion protein

Country Status (6)

Country Link
CL (1) CL2020001122A1 (en)
CR (1) CR20200240A (en)
DO (1) DOP2020000079A (en)
MX (1) MX2017013995A (en)
PE (1) PE20201348A1 (en)
WO (1) WO2019087108A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130043168A (en) * 2010-06-24 2013-04-29 아비에 인코포레이티드 Dual variable domain immunoglobulins and uses thereof
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
EA028520B1 (en) * 2011-10-18 2017-11-30 Кохерус Байосайенсис, Инк. Etanercept formulations stabilized with meglumine
AU2013290289B2 (en) * 2012-07-09 2018-03-29 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles

Also Published As

Publication number Publication date
PE20201348A1 (en) 2020-11-30
CL2020001122A1 (en) 2020-10-02
DOP2020000079A (en) 2020-09-15
MX2017013995A (en) 2019-05-01
WO2019087108A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
PH12017500844A1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
PE20200513A1 (en) STABLE FORMULATIONS OF ANTIBODIES AGAINST PROGRAMMED DEATH RECEIVER 1 (PD-1) AND METHODS FOR THEIR USE
AR107014A1 (en) PHARMACEUTICAL FORMULATION WATER
EP4233892A3 (en) Stable anti-ifnar1 formulation
NZ708103A (en) Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
MX2018005194A (en) Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same.
NZ603900A (en) Subcutaneous anti-her2 antibody formulation
NZ719036A (en) Anti-pdl1 antibody formulations
NZ629261A (en) Pharmaceutical formulations of tnf-alpha antibodies
NZ613809A (en) Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
AR058567A1 (en) FORMULATIONS OF STABLE PROTEINS
HRP20160434T1 (en) Abeta antibody formulation
AR086344A1 (en) METHODS OF TREATMENT OR PREVENTION OF DISORDERS RELATED TO CHOLESTEROL
RS54769B1 (en) Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody
NZ705178A (en) Anti-prolactin receptor antibody formulations
AR071852A1 (en) PHARMACEUTICAL FORMULATION OF AN ANTIBODY AGAINST OX40L
WO2012141978A2 (en) Formulations with reduced viscosity
MX2021002935A (en) Csf-1r antibody formulation.
EA200970274A1 (en) METHODS OF ADMINISTRATION OF HYPOGLYCEMIC MEANS WITH LONG TERM
EP2694100A1 (en) Formulations with reduced viscosity
AR100268A1 (en) LIQUID FORMULATION INCLUDING GM-CSF NEUTRALIZING COMPOUND
US20160120946A1 (en) Compositions comprising gc-macrophage activating factor and uses thereof
JP2017516848A5 (en)
CR20200240A (en) Stable pharmaceutical formulation of a fusion protein
CN103505729B (en) A kind of stable rabies virus human antibody combination preparation